Pancreatic ductal adenocarcinoma (PDAC) remains one of the most treatment-refractory malignancies, with limited and often transient benefit from chemotherapy, targeted therapy, imm
This is a narrative review synthesizing preclinical mechanistic evidence and proposing PSMD14 as a therapeutic target, but it does not report new empirical data, clinical trials, or outcomes in patients.